Scoopfeeds — Intelligent news, curated.
Leerink reiterates Eli Lilly stock rating on gene therapy progress
business

Leerink reiterates Eli Lilly stock rating on gene therapy progress

Investing.com · May 26, 2026, 7:53 AM

Leerink reiterates Eli Lilly stock rating on gene therapy progress

Read full story on Investing.com → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop